Four week, double-blind, placebo controlled phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in children and adolescents with bipolar I disorder (manic or mixed).
Latest Information Update: 26 Mar 2021
At a glance
- Drugs Ziprasidone (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Sponsors Viatris Inc
- 05 Dec 2011 Actual end date for the extension trial (NCT00265330) is January 2008.
- 05 Dec 2011 Actual end date for the extension trial (NCT00265330) is January 2008.
- 05 Dec 2011 Actual start date for the extension trial (NCT00265330) is March 2006.